The incidence of fungal infections has increased significantly over the past two decades. The National Nosocomial Infections Surveillance System (Atlanta, Ga.) has found a sharp rise in the incidence of yeast fungemias between 1980 and 1989 (1). Since many of the yeasts associated with human infections have been found to be innately resistant or to develop resistance to the most common antifungal agents, the introduction of appropriate therapy for these invasive infections depends largely on the rapid and accurate identification of the etiologic agents. For example, Candida lusitaniae has been reported to be resistant in vitro to amphotericin B, while Candida krusei and Candida glabrata have been found to be resistant to fluconazole